IL6 and lung cancer: Enriched tumor markers, inflammatory imbalance, particularly the IL-6/IL-10 ratio, enhanced ctDNA detection, and local immunosuppressive immune features support the utility of BALF as a minimally invasive liquid biopsy for lung cancer evaluation and risk stratification.